Pliant Therapeutics (PLRX) Operating Leases (2021 - 2026)

Pliant Therapeutics (PLRX) has 6 years of Operating Leases data on file, last reported at $28.8 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $28.8 million, down 3.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.8 million (down 3.7% YoY), and the FY2025 annual result was $27.7 million, down 6.05% from the prior year.
• Operating Leases rose to $28.8 million in Q1 2026 per PLRX's latest filing, from $27.7 million in the prior quarter.
• Over five years, Operating Leases peaked at $29.9 million in Q1 2025 and troughed at $2.3 million in Q2 2023.
• A 5-year average of $17.2 million and a median of $23.7 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2023 and 2024: Operating Leases sank 58.81% in 2023, then soared 731.58% in 2024.
• A 5-year view of Operating Leases shows it stood at $3.4 million in 2022, then sank by 32.4% to $2.3 million in 2023, then surged by 1170.02% to $29.4 million in 2024, then slipped by 6.05% to $27.7 million in 2025, then advanced by 4.07% to $28.8 million in 2026.
• Business Quant data shows PLRX's Operating Leases at $28.8 million in Q1 2026, $27.7 million in Q4 2025, and $29.4 million in Q3 2025.